Abstract:LINC01126 is highly expressed in castration‐resistant prostate cancer and is correlated with poor prognosis. AR‐targeted therapies upregulate LINC01126 expression through relieving its transcriptional repression by AR. LINC01126 facilitates the activation of AR signalling independent of androgen. LINC01126 promotes the transition from O‐GlcNAcylation at threonine 80 to phosphorylation at S81 within the AR protein. AR‐targeted therapies inhibit synthesis of AR ligand or block binding of AR ligand to AR. Without AR ligand, AR protein is O‐GlcNAcylated at threonine 80 and degrades rapidly. LINC01126 is transcriptionally repressed by AR. AR‐targeted therapies thereby upregulate LINC01126 expression through relieving its transcriptional repression by AR. LINC01126 facilitates the interaction of AR with CDK9, resulting in AR S81 phosphorylation. Consequences of AR S81 phosphorylation are analogous to the effect of androgen on AR stability, nuclear translocation and transactivation. Therefore, LINC01126 facilitates the activation of AR signalling independent of androgen, contributing to progression of CRPC. LINC01126‐ASO that specifically interferes the binding of AR to CDK9 may have a possible therapeutic effect on CRPC. Background Prostate cancer (PCa) initially shows satisfactory response to therapies targeting the androgen receptor (AR). However, progression to a castration‐resistant stage indicates poor prognosis in PCa patients. AR signalling still plays a central role in most castration‐resistant prostate cancers (CRPC). Therefore, unveiling the mechanisms of AR reactivation under androgen‐deprived conditions is imperative to discover novel therapeutic targets for CRPC. Methods Using an integrative analysis of the transcriptomics of three independent PCa cohorts and a published landscape of AR‐regulated long non‐coding RNA (lncRNA), lncRNA LINC01126 was selected as a candidate gene that could drive CRPC progression for further study. Quantitative reverse transcription polymerase chain reaction, in situ hybridisation (ISH) and fluorescent ISH were performed to detect LINC01126 in PCa tissues and cells. The functional role and mechanism of LINC01126 were further investigated using in vitro and in vivo gain and loss of function assays. Results LINC01126, identified as an AR‐repressed lncRNA, was significantly upregulated after AR‐targeted therapies. In addition, we found that LINC01126 was upregulated in CRPC and was associated with poor prognosis. We also proved that LINC01126 stabilised AR protein and enhanced AR nuclear translocation and transactivation by promoting the transition from O‐GlcNAcylation at threonine 80 to phosphorylation at serine 81 (S81) within the AR protein. Mechanism analysis revealed that LINC01126 facilitates the interaction of CDK9 with AR and impedes the binding of O‐linked N‐acetylglucosamine (O‐GlcNAc) transferase to AR. Consequently, LINC01126 expression was sufficient to activate AR signalling without androgen. LINC01126 overexpression increased, whereas LINC01126 knockdown decreased castration resistance traits in PCa cells in vitro and in vivo. Furthermore, our data showed that LINC01126‐targeting antisense oligonucleotides (ASO) substantially inhibited CRPC cells in vitro. Conclusions Our research expands the functions of AR‐regulated lncRNA in sustaining androgen‐independent AR activity and promoting CRPC progression and reveals that LINC01126 may be a new therapeutic target for PCa.

Integrative analysis identifies the atypical repressor E2F8 as a targetable transcriptional activator driving lethal prostate cancer

E2F1 Renders Prostate Cancer Cell Resistant to ICAM-1 Mediated Antitumor Immunity by NF-κB Modulation.

Integrative analysis identifies targetable CREB1/FoxA1 transcriptional co-regulation as a predictor of prostate cancer recurrence

Orphan Nuclear Receptor TLX Contributes to Androgen Insensitivity in Castration-Resistant Prostate Cancer Via Its Repression of Androgen Receptor Transcription.

RNF8 Up-Regulates AR/ARV7 Action to Contribute to Advanced Prostate Cancer Progression.

Anti-androgen Therapy Induces Transcriptomic Reprogramming in Metastatic Castration-Resistant Prostate Cancer in a Murine Model.

Abstract LB-085: RB Loss-Induced Genome Wide E2F1 Reprogramming Drive Advanced Prostate Cancer

Chromatin Profiles Classify Castration-Resistant Prostate Cancers Suggesting Therapeutic Targets.

Chromatin Accessibility Profiles of Castration-Resistant Prostate Cancers Reveal Novel Subtypes and Therapeutic Vulnerabilities

Abstract B11: Re-wired E2F function in response to RB loss as a potential driver of castration-resistant prostate cancer

Integrative Analysis of AR-mediated Transcriptional Regulatory Network Reveals IRF1 As an Inhibitor of Prostate Cancer Progression.

An Atlas of Accessible Chromatin in Advanced Prostate Cancer Reveals the Epigenetic Evolution during Tumor Progression

Abstract B026: Chromatin Profiles Classify Castration-Resistant Prostate Cancers Suggesting Therapeutic Targets

Abstract 6544: Targeting resistance mechanisms to AR-targeted therapy in prostate cancer through inhibition of CREBBP/EP300

Androgen Receptor Signaling and Spatial Chromatin Organization in Castration-Resistant Prostate Cancer

TRAF4-mediated nonproteolytic ubiquitination of androgen castration-resistant cancer

LINC00675 Activates Androgen Receptor Axis Signaling Pathway to Promote Castration-Resistant Prostate Cancer Progression

Canonical androgen response element motifs are tumor suppressive regulatory elements in the prostate

Androgen‐repressed lncRNA LINC01126 drives castration‐resistant prostate cancer by regulating the switch between O‐GlcNAcylation and phosphorylation of androgen receptor

CRISPR screening identifies CDK12 as a conservative vulnerability of prostate cancer

Activation of P-TEFb by Androgen Receptor-Regulated Enhancer RNAs in Castration-Resistant Prostate Cancer.